• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Consumer Cyclical·000972.SZ
Share

Chalkis Health Industry Co., Ltd Stocks

CN¥ 3.57Last Updated 08.07.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 414.13M

CN¥ 3.57
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Chalkis Health Industry Co., Ltd. operates internationally, specializing in the cultivation, processing, and sale of tomatoes. Its diverse product portfolio includes concentrated tomato paste, available in drums and wooden bins; prepared tomato varieties such as peeled, diced, and canned goods; innovative tomato-derived products like fiber sheets and seed oil; and health supplements, specifically lycopene capsules. The company, headquartered in Urumqi, China, adopted its current name, Chalkis Health Industry Co., Ltd., in May 2016, having previously been known as Xinjiang Chalkis Co., Ltd.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is 'expensive' on EV/EBITDA, und

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

08.07.2026 14:33

The Iran conflict will add nearly $4 billion to ExxonMobil's quarterly profits

08.07.2026 13:33

Trump Declared the Ceasefire with Iran Over

08.07.2026 13:17

Chinese stocks in Hong Kong posted a 15-month high amid a rally in the IT sector

08.07.2026 12:48

OpenAI has announced the date for the public release of its new AI systems. The release was delayed due to the White House.

08.07.2026 11:00

Where to Invest $10,000 in July: Focus on Payments, Banks, and Microsoft

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026